Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
NCT02114268 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2014
- Completion date
- June 30, 2015
- Enrollment
- 342 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.